155 related articles for article (PubMed ID: 38660130)
21. Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Liu L; Suo T; Shen Y; Geng C; Song Z; Liu F; Wang J; Xie Y; Zhang Y; Tang T; Zhang L; Wang W
Qual Life Res; 2020 Nov; 29(11):3009-3015. PubMed ID: 32564293
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
[TBL] [Abstract][Full Text] [Related]
24. Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
Veitch ZW; Shepshelovich D; Gallagher C; Wang L; Abdul Razak AR; Spreafico A; Bedard PL; Siu LL; Minasian L; Hansen AR
J Natl Cancer Inst; 2021 Aug; 113(8):980-988. PubMed ID: 33616650
[TBL] [Abstract][Full Text] [Related]
25. Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events.
Yang SS; Chen L; Liu Y; Lu HJ; Huang BJ; Lin AH; Sun Y; Ma J; Xie FY; Mao YP
BMC Cancer; 2021 Jul; 21(1):860. PubMed ID: 34315423
[TBL] [Abstract][Full Text] [Related]
26. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
Suzuki Y; Iwamoto T; Uno M; Hatono M; Kajiwara Y; Takahashi Y; Kochi M; Shien T; Kikawa Y; Uemura Y; Hagiwara Y; Yamamoto S; Taira N; Doihara H; Toyooka S
Breast Cancer; 2023 Sep; 30(5):856-868. PubMed ID: 37422608
[TBL] [Abstract][Full Text] [Related]
28. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
[TBL] [Abstract][Full Text] [Related]
29. Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Wang TQ; Samuel JN; Brown MC; Vennettilli A; Solomon H; Eng L; Liang M; Gill G; Merali Z; Tian C; Cheng NYH; Campbell M; Patel D; Liu AX; Liu G; Howell D
Oncol Ther; 2018 Dec; 6(2):189-201. PubMed ID: 32700029
[TBL] [Abstract][Full Text] [Related]
30. Multicenter Prospective Cohort Study of the Patient-Reported Outcome Measures PRO-CTCAE and CAT EORTC QLQ-C30 in Major Abdominal Cancer Surgery (PATRONUS): A Student-Initiated German Medical Audit (SIGMA) Study.
; Mihaljevic AL
Ann Surg Oncol; 2021 Jun; 28(6):3075-3089. PubMed ID: 33683524
[TBL] [Abstract][Full Text] [Related]
31. Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period.
Lee MK; Basch E; Mitchell SA; Minasian LM; Langlais BT; Thanarajasingam G; Ginos BF; Rogak LJ; Mendoza TR; Bennett AV; Schrag D; Mazza GL; Dueck AC
Qual Life Res; 2023 Jul; 32(7):2047-2058. PubMed ID: 36897529
[TBL] [Abstract][Full Text] [Related]
32. Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
Zhu Y; Jean-Baptiste M; Lenderking WR; Bell JA; Revicki DA; Lin HM; Brake R; Reeve BB
Cancer Med; 2023 Mar; 12(5):5494-5505. PubMed ID: 36583557
[TBL] [Abstract][Full Text] [Related]
33. Choice of a patient-reported outcome measure for patients with anal cancer for use in cancer clinical trials and routine clinical practice: a mixed methods approach.
Gilbert A; Francischetto EO; Blazeby J; Holch P; Davidson S; Sebag-Montefiore D; Velikova G
Lancet; 2015 Feb; 385 Suppl 1():S38. PubMed ID: 26312860
[TBL] [Abstract][Full Text] [Related]
34. Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy.
Taarnhøj GA; Lindberg H; Johansen C; Pappot H
J Patient Rep Outcomes; 2019 Aug; 3(1):56. PubMed ID: 31440865
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
[TBL] [Abstract][Full Text] [Related]
36. Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers.
Günther M; Hentschel L; Schuler M; Müller T; Schütte K; Ko YD; Schmidt-Wolf I; Jaehde U
BMC Cancer; 2023 Jul; 23(1):629. PubMed ID: 37407982
[TBL] [Abstract][Full Text] [Related]
37. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.
Reeve BB; McFatrich M; Pinheiro LC; Freyer DR; Basch EM; Baker JN; Withycombe JS; Sung L; Mack JW; Waldron MK; Mowbray C; Palma D; Hinds PS
J Pain Symptom Manage; 2017 Apr; 53(4):759-766. PubMed ID: 28062347
[TBL] [Abstract][Full Text] [Related]
38. Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology.
Sandler KA; Mitchell SA; Basch E; Raldow AC; Steinberg ML; Sharif J; Cook RR; Kupelian PA; McCloskey SA
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):44-52. PubMed ID: 30102201
[TBL] [Abstract][Full Text] [Related]
39. Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure.
Feldman E; Pos FJ; Smeenk RJ; van der Poel H; van Leeuwen P; de Feijter JM; Hulshof M; Budiharto T; Hermens R; de Ligt KM; Walraven I
ESMO Open; 2023 Feb; 8(1):100775. PubMed ID: 36652781
[TBL] [Abstract][Full Text] [Related]
40. Comparison of EORTC QLQ-C30 and PRO-CTCAE™ Questionnaires on Six Symptom Items.
Taarnhøj GA; Kennedy FR; Absolom KL; Bæksted C; Vogelius IR; Johansen C; Velikova G; Pappot H
J Pain Symptom Manage; 2018 Sep; 56(3):421-429. PubMed ID: 29807157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
